p.102 抽出テキスト
783. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581–4. https://doi.org/10.1016/s0140-6736(87) 90231-5 784. Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European working party on high blood pressure in the elderly. BMJ 1989; 298:1552–6. https://doi.org/10.1136/bmj.298.6687.1552 785. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017;389:2226–37. https://doi.org/10. 1016/s0140-6736(17)30754-7 786. Böhm M, Ferreira JP, Mahfoud F, Duarte K, Pitt B, Zannad F, et al. Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. Eur Heart J 2020;41:1673–83. https://doi.org/ 10.1093/eurheartj/ehaa132 787. McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol 2016;68:1713–22. https://doi.org/ 10.1016/j.jacc.2016.07.754 788. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:1874–2071. https://doi.org/10.1097/hjh. 0000000000003480 789. Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers M P, Franco L J, et al. Blood pressure in four remote populations in the INTERSALT study. Hypertension 1989; 14:238–46. https://doi.org/10.1161/01.hyp.14.3.238 790. Birrane JP, Foschi M, Sacco S, McEvoy JW. Another nail in the coffin of causality for the diastolic blood pressure J curve. Hypertension 2022;79:794–7. https://doi.org/10.1161/ hypertensionaha.122.18997 791. Mueller NT, Noya-Alarcon O, Contreras M, Appel LJ, Dominguez-Bello MG. Association of age with blood pressure across the lifespan in isolated Yanomami and Yekwana villages. JAMA Cardiol 2018;3:1247–9. https://doi.org/10.1001/jamacardio. 2018.3676 792. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, et al. The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care 2020;43:1878–84. https://doi.org/10.2337/dc19-2047 793. Shihab S, Boucher RE, Abraham N, Wei G, Beddhu S. Influence of baseline diastolic blood pressure on the effects of intensive systolic blood pressure lowering on the risk of stroke. Hypertension 2022;79:785–93. https://doi.org/10.1161/hypertensionaha. 121.18172 794. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 561–632. https://doi.org/10.1093/eurheartj/ehab395 795. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368 796. Mancusi C, de Simone G, Brguljan Hitij J, Sudano I, Mahfoud F, Parati G, et al. Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother 2021;7: 242–50. https://doi.org/10.1093/ehjcvp/pvaa040 797. Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, et al. Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: the simvastatin ezetimibe in aortic stenosis study (SEAS). Circulation 2016;134:455–68. https:// doi.org/10.1161/circulationaha.115.021213 798. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/ eurheartj/ehad195 799. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003;362:777–81. https://doi.org/10. 1016/s0140-6736(03)14285-7 800. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. https://doi.org/10.1056/NEJMoa1313731 801. Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Dehghan A, Byrne KS, et al. Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study. Genome Med 2021;13:38. https://doi.org/10.1186/ s13073-021-00849-3 802. Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol 2017;46:162–72. https://doi.org/10.1093/ije/dyw053 803. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 373–498. https://doi.org/10.1093/eurheartj/ehaa612 804. Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities. Alzheimers Dement (N Y) 2019;5:107–17. https:// doi.org/10.1016/j.trci.2019.02.001 805. Georgakis MK, Duering M, Wardlaw JM, Dichgans M. WMH and long-term outcomes in ischemic stroke: a systematic review and meta-analysis. Neurology 2019;92: e1298–308. https://doi.org/10.1212/wnl.0000000000007142 806. Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, et al. Global burden of small vessel disease-related brain changes on MRI predicts cognitive and functional decline. Stroke 2020;51:170–8. https://doi.org/10.1161/strokeaha.119.026170 807. Potter T, Lioutas VA, Tano M, Pan A, Meeks J, Woo D, et al. Cognitive impairment after intracerebral hemorrhage: a systematic review of current evidence and knowledge gaps. Front Neurol 2021;12:716632. https://doi.org/10.3389/fneur.2021.716632 808. Wang F, Hua S, Zhang Y, Zhu J, Liu R, Jiang Z. Association between small vessel disease markers, medial temporal lobe atrophy and cognitive impairment after stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2021;30:105460. https:// doi.org/10.1016/j.jstrokecerebrovasdis.2020.105460 809. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol 2021;17:639–54. https://doi.org/10.1038/s41581-021-00430-6 810. Kelly D, Rothwell PM. Disentangling the multiple links between renal dysfunction and cerebrovascular disease. J Neurol Neurosurg Psychiatry 2020;91:88–97. https://doi.org/ 10.1136/jnnp-2019-320526 811. Papanastasiou CA, Theochari CA, Zareifopoulos N, Arfaras-Melainis A, Giannakoulas G, Karamitsos TD, et al. Atrial fibrillation is associated with cognitive impairment, allcause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis. J Gen Intern Med 2021;36:3122–35. https://doi.org/10.1007/s11606- 021-06954-8 812. Li J, Wu Y, Zhang D, Nie J. Associations between heart failure and risk of dementia: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2020;99:e18492. https://doi. org/10.1097/md.0000000000018492 813. Canavan M, O’Donnell MJ. Hypertension and cognitive impairment: a review of mechanisms and key concepts. Front Neurol 2022;13:821135. https://doi.org/10.3389/ fneur.2022.821135 814. Dawson J, Béjot Y, Christensen LM, De Marchis GM, Dichgans M, Hagberg G, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J 2022;7:I–XLI. https://doi.org/10.1177/23969873221100032 815. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52:e364–467. https://doi.org/10.1161/str.0000000000000375 816. Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan RJ, Roos YB, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2018;7:CD007858. https://doi.org/10.1002/14651858. CD007858.pub2 817. Boncoraglio GB, Del Giovane C, Tramacere I. Antihypertensive drugs for secondary prevention after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2021;52:1974–82. https://doi.org/10.1161/strokeaha.120.031945 818. Fischer U, Cooney MT, Bull LM, Silver LE, Chalmers J, Anderson CS, et al. Acute poststroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study. Lancet Neurol 2014;13:374–84. https://doi.org/10.1016/s1474-4422(14)70031-6 819. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225–37. https://doi.org/10.1056/NEJMoa0804593 820. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41. https://doi.org/10.1016/s0140- 6736(01)06178-5 821. McGurgan IJ, Kelly PJ, Turan TN, Rothwell PM. Long-term secondary prevention: management of blood pressure after a transient ischemic attack or stroke. Stroke 2022;53: 1085–103. https://doi.org/10.1161/strokeaha.121.035851 822. Rudd AG, Bowen A, Young GR, James MA. The latest national clinical guideline for stroke. Clin Med (Lond) 2017;17:154–5. https://doi.org/10.7861/clinmedicine.17-2-154 ESC Guidelines 4013 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026